ArticleDiscover oncology2026
MiR-3928 functions as a tumor suppressor and prognostic factor in colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IQGAP3, the overlooked oncogenic twin of IQGAP1: mapping its interactome and functional roles across cellular signaling and cancer.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a digestive tract tumor and ranks as the third most common malignant tumor globally. PURPOSE: This study aimed to confirm the effects of miR-3928/IQGAP3 on the development and prognosis of CRC.
methodsWe assessed the prognostic value of miR-3928 through survival analyses using Kaplan-Meier plots and Cox regression modeling. The interaction between miR-3928 and IQGAP3 was confirmed by RT-qPCR and Dual-Luciferase assay. We used CCK8, Transwell assay, and colony formation assay to examine their effects on SW480 and HT29 cell proliferation and migration.
resultsLow miR-3928 expression correlates with poor prognosis in CRC patients, while IQGAP3 is highly expressed in CRC. MiR-3928 targets and regulates IQGAP3. Overexpression of miR-3928 inhibits the proliferation and migration of CRC cells, but overexpression of IQGAP3 reverses this effect. Additionally, miR-3928 overexpression promotes ferroptosis, which may be a key mechanism underlying its ability to inhibit CRC cell proliferation.
conclusionIn CRC, low miR-3928 expression correlates with poor prognosis. MiR-3928 suppresses CRC cell proliferation and migration by targeting IQGAP3, possibly through ferroptosis promotion. This study confirms that miR-3928 acts as a tumor suppressor in CRC, offering a potential target for prognostic evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.